(506) Electrosprayed Dry Powder Inhaler (DPI) Formulations of Bevacizumab for the Treatment of NSCLC
Introduction: Cancer is now the second leading cause of death worldwide, with lung cancer having the highest incidence and mortality rates. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, making it a major research focus.1 Pulmonary delivery via DPIs provides rapid onset, targeted therapy, and better compliance.2 Electrospray technology ensures uniform, small particles suitable for pulmonary delivery. Bevacizumab is a first-line FDA-approved monoclonal antibody for NSCLC, targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis and reduce tumour blood supply.3
Learning Objectives:
Understand the benefits of pulmonary drug delivery via dry powder inhalers for NSCLC treatment.
Recognise electrospray principles and its role in enhancing formulations for pulmonary delivery.
Learn methods to assess Bevacizumab's encapsulation, activity, and anticancer mechanism.
